Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?

Yazan F. Madanat, Matt E. Kalaycio, Aziz Nazha

Research output: Contribution to journalArticle

Abstract

The aim of this review is to summarize the data on commonly mutated genes and genomic pathways in acute myeloid leukemia (AML) with a focus on recently approved targeted therapies. AML is a heterogeneous disease with recurrent cytogenetic and genomic abnormalities that define the disease biology and pathogenesis. Classification of the disease categories and their prognostication was updated in the past 2 years to reflect the most recent advances in understanding the complex disease biology of AML. This review highlights major updates in the World Health Organization classification, including cytogenetic re-classifications, provisional entities, and updates to the European Leukemia Net (ELN) AML risk group stratification. An overview of pivotal studies that used novel sequencing techniques to define the mutational landscape of AML is also provided. In these studies, mutations are classified into subgroups based on functional pathways and are used to understand various interactions and mutual exclusivity of some mutations, suggesting important roles in disease evolution and AML pathogenesis. The complex interactions between mutations can dictate outcomes as well as possibly predict disease phenotypes after correcting for clinical variables. CONCLUSION: Genomic testing in AML using next generation sequencing has become widely available and a new standard of care for all patients. Therefore, it is vital to use novel methods to incorporate these data in clinical decision making.

Original languageEnglish (US)
Pages (from-to)35-44
Number of pages10
JournalActa medica academica
Volume48
Issue number1
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Genomics
Acute Myeloid Leukemia
Mutation
Standard of Care
Cytogenetics
Chromosome Aberrations
Leukemia
Phenotype
Genes

Keywords

  • AML
  • Mutation
  • Myeloid
  • NGS, Biology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018? / Madanat, Yazan F.; Kalaycio, Matt E.; Nazha, Aziz.

In: Acta medica academica, Vol. 48, No. 1, 01.04.2019, p. 35-44.

Research output: Contribution to journalArticle

Madanat, Yazan F. ; Kalaycio, Matt E. ; Nazha, Aziz. / Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?. In: Acta medica academica. 2019 ; Vol. 48, No. 1. pp. 35-44.
@article{df65536589734c52ac06411a20f87390,
title = "Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?",
abstract = "The aim of this review is to summarize the data on commonly mutated genes and genomic pathways in acute myeloid leukemia (AML) with a focus on recently approved targeted therapies. AML is a heterogeneous disease with recurrent cytogenetic and genomic abnormalities that define the disease biology and pathogenesis. Classification of the disease categories and their prognostication was updated in the past 2 years to reflect the most recent advances in understanding the complex disease biology of AML. This review highlights major updates in the World Health Organization classification, including cytogenetic re-classifications, provisional entities, and updates to the European Leukemia Net (ELN) AML risk group stratification. An overview of pivotal studies that used novel sequencing techniques to define the mutational landscape of AML is also provided. In these studies, mutations are classified into subgroups based on functional pathways and are used to understand various interactions and mutual exclusivity of some mutations, suggesting important roles in disease evolution and AML pathogenesis. The complex interactions between mutations can dictate outcomes as well as possibly predict disease phenotypes after correcting for clinical variables. CONCLUSION: Genomic testing in AML using next generation sequencing has become widely available and a new standard of care for all patients. Therefore, it is vital to use novel methods to incorporate these data in clinical decision making.",
keywords = "AML, Mutation, Myeloid, NGS, Biology",
author = "Madanat, {Yazan F.} and Kalaycio, {Matt E.} and Aziz Nazha",
year = "2019",
month = "4",
day = "1",
doi = "10.5644/ama2006-124.240",
language = "English (US)",
volume = "48",
pages = "35--44",
journal = "Acta medica academica",
issn = "1840-1848",
publisher = "Academy of Sciences and Arts of Bosnia and Herzegovina",
number = "1",

}

TY - JOUR

T1 - Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?

AU - Madanat, Yazan F.

AU - Kalaycio, Matt E.

AU - Nazha, Aziz

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The aim of this review is to summarize the data on commonly mutated genes and genomic pathways in acute myeloid leukemia (AML) with a focus on recently approved targeted therapies. AML is a heterogeneous disease with recurrent cytogenetic and genomic abnormalities that define the disease biology and pathogenesis. Classification of the disease categories and their prognostication was updated in the past 2 years to reflect the most recent advances in understanding the complex disease biology of AML. This review highlights major updates in the World Health Organization classification, including cytogenetic re-classifications, provisional entities, and updates to the European Leukemia Net (ELN) AML risk group stratification. An overview of pivotal studies that used novel sequencing techniques to define the mutational landscape of AML is also provided. In these studies, mutations are classified into subgroups based on functional pathways and are used to understand various interactions and mutual exclusivity of some mutations, suggesting important roles in disease evolution and AML pathogenesis. The complex interactions between mutations can dictate outcomes as well as possibly predict disease phenotypes after correcting for clinical variables. CONCLUSION: Genomic testing in AML using next generation sequencing has become widely available and a new standard of care for all patients. Therefore, it is vital to use novel methods to incorporate these data in clinical decision making.

AB - The aim of this review is to summarize the data on commonly mutated genes and genomic pathways in acute myeloid leukemia (AML) with a focus on recently approved targeted therapies. AML is a heterogeneous disease with recurrent cytogenetic and genomic abnormalities that define the disease biology and pathogenesis. Classification of the disease categories and their prognostication was updated in the past 2 years to reflect the most recent advances in understanding the complex disease biology of AML. This review highlights major updates in the World Health Organization classification, including cytogenetic re-classifications, provisional entities, and updates to the European Leukemia Net (ELN) AML risk group stratification. An overview of pivotal studies that used novel sequencing techniques to define the mutational landscape of AML is also provided. In these studies, mutations are classified into subgroups based on functional pathways and are used to understand various interactions and mutual exclusivity of some mutations, suggesting important roles in disease evolution and AML pathogenesis. The complex interactions between mutations can dictate outcomes as well as possibly predict disease phenotypes after correcting for clinical variables. CONCLUSION: Genomic testing in AML using next generation sequencing has become widely available and a new standard of care for all patients. Therefore, it is vital to use novel methods to incorporate these data in clinical decision making.

KW - AML

KW - Mutation

KW - Myeloid

KW - NGS, Biology

UR - http://www.scopus.com/inward/record.url?scp=85069262316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069262316&partnerID=8YFLogxK

U2 - 10.5644/ama2006-124.240

DO - 10.5644/ama2006-124.240

M3 - Article

C2 - 31264431

AN - SCOPUS:85069262316

VL - 48

SP - 35

EP - 44

JO - Acta medica academica

JF - Acta medica academica

SN - 1840-1848

IS - 1

ER -